AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.

AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.

AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).

Sales and UpgradesContent Updates
Features and Benefits icon

Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs

Features and Benefits icon

Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals

Features and Benefits icon

Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives

Features and Benefits icon

Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties

Publication Updates

08 Nov
AHFS Drug Information logo
AHFS November 2022 Update

This update contains 7 new monographs and 25 revised monographs.

New monographs: DaxibotulinumtoxinA-lanm; Deucravacitinib; Dextromethorphan and Bupropion; Olipudase Alfa-rpcp; Oteseconazole; Spesolimab-sbzo (Topical); Terlipressin

Revised monographs: Abatacept; ALPRAZolam; Benzodiazepines General Statement; chlordiazePOXIDE; cloBAZam; clonazePAM; Clorazepate; COVID-19 Vaccine (Moderna); COVID-19 Vaccine (Pfizer-BioNTech); Crizotinib; diazePAM; Erlotinib; Estazolam; Flurazepam; Glecaprevir and Pibrentasvir; LORazepam; Maralixibat; Midazolam; Neratinib; Oxazepam; Panobinostat; Quazepam; Siponimod; Temazepam; Triazolam

11 Oct
AHFS Drug Information logo
AHFS October 2022 Update

This update contains 2 new monographs and 23 revised monographs.

New monographs: COVID-19 Vaccine (Novavax); Roflumilast (Topical).

Revised monographs: Alemtuzumab (MS); Bebtelovimab; Dasiglucagon; Dimethyl Fumarate; Diroximel Fumarate; Fingolimod Hydrochloride; Gefitinib; Glatiramer Acetate; Glucagon; Glycopyrronium tosylate; Maribavir; Monomethyl Fumarate; Natalizumab; Nirmatrelvir and Ritonavir; Odevixibat; Ofatumumab (Multiple Sclerosis); Osilodrostat Phosphate; Ozanimod Hydrochloride; Ponesimod; Ruxolitinib Phosphate (Topical); Sofosbuvir and Velpatasvir; Tildrakizumab-asmn; Vismodegib.

13 Sep
AHFS Drug Information logo
AHFS September 2022 Update

This update contains 2 new monographs and 16 revised monographs.

New monographs: Ganaxolone; Vutrisiran

Revised monographs: Alectinib; Bosutinib; Cabozantinib; Decitabine and Cedazuridine, Erdafitinib, Inotersen, Lanreotide; Lemborexant; Osimertinib; Patisiran; romiPLOStim; Ruxolitinib; Sarilumab; SORAfenib; Suvorexant; Tecovirimat.

09 Aug
AHFS Drug Information logo
AHFS August 2022 Update

This update contains 14 revised monographs and 2 new MedWatch alerts.

Revised monographs: Abemaciclib; Anakinra; COVID-19 Vaccine (Moderna); COVID-19 Vaccine (Pfizer-BioNTech); Elbasvir and Grazoprevir; Ixekizumab; Larotrectinib; Lorlatinib; Pexidartinib; Semaglutide; Trifluridine and Tipiracil; Ustekinumab; Vandetanib; Vemurafenib

New MedWatch alerts on the following monographs: Duvelisibl; Umbralisib

12 Jul
AHFS Drug Information logo
AHFS July 2022 Update

This update contains 3 new monographs and 16 revised monographs.

New monographs: Sirolimus (Topical); Daridorexant; Mavacamten

Revised monographs: SUNItinib; Cabergoline; Enzalutamide; Trametinib Dimethyl Sulfoxide; Rotigotine; Secukinumab; Galcanezumab-gnlm; Tafamidis; Alpelisib; Elexacaftor, Tezacaftor, and Ivacaftor; Ubrogepant; Cenobamate; Ozanimod; Selumetinib; Atogepant; rOPINIRole

14 Jun
AHFS Drug Information logo
AHFS June 2022 Update

This update contains 15 revised monographs.

Revised monographs: Aducanumab; Apomorphine; Afatinib; Axitinib; Baricitinib; Bromocriptine; Fingolimod; Golimumab; Guselkumab; Pemigatinib; Ponesimod; Regorafenib; Ribociclib; Risankizumab-rzaa; Tofacitinib.

View more View all content updates